Cash-Healthy Achillion Plans to Raise $125M Via Offering
By Randy Osborne
Friday, February 22, 2013
With its hepatitis C virus (HCV) pipeline percolating and $77.4 million in the coffers as of the end of last year, Achillion Pharmaceuticals Inc. disclosed its plan to begin a public offering that would raise $125 million more, pursuant to a shelf registration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.